Curaleaf Holding: Forging the largest acquisition in U.S cannabis landscape
The shares of Curaleaf (OTCQX: CURLF) surged by almost 15% since the news of its acquisition of Cura Partners, the owner of Select brand,...
Coverage
- All
- Beauty
- Biotechnology
- Cannabis
- Communications
- Education
- Energy
- Entertainment
- Environment
- ETFs
- Finance
- Fitness
- Food and Beverage
- Healthcare
- Hospitality
- Insider Trading
- Investing Ideas
- Macro
- Market Insight
- Miscellaneous
- Power
- Real Estate
- Retail
- Sectors
- Security
- Startups
- Technologies
- Trending
- Uncategorized
Recent Advances in Gene Therapy and Small Molecule Inhibitors show promise in Sjogren’s Syndrome
Sjogren’s, named after its discoverer Henrik Sjögren, is the most prevalent systemic autoimmune disease that predominantly affects women. This disorder is manifested in...
Research in Crohn’s Disease poised to change the Treatment Landscape
Crohn’s is an inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract, chronic diarrhea, abdominal cramps, rectal bleeding and constipation to...
How to Ascertain the Optimal Amount for Your Seed Round
Seed capital or funding is the initial capital required to get the company on its feet. It is not only crucial in helping...
Emerging treatment approaches in Pruritus
Pruritus is characterized by an uncomfortable and persistent urge to scratch caused either due to a skin disorder or an underlying systemic disease...
Acreage Holdings – “On a High” with news of Acquisition by Canopy Growth
The Canadian cannabis behemoth Canopy Growth Inc (NYSE:CGC), a global leader in diversified cannabis and hemp related products, entered into a definitive agreement with Acreage...
Emerging Therapeutics in Preeclampsia Management
Preeclampsia is a pregnancy related complication that affects over 5% to 8% of pregnancies or about 3,00,000 women in the US alone. An...
Cyberdyne – Changing Paradigms of Exoskeleton Market
Cyberdyne’s (OTC Pink: CYBQY) HAL (Hybrid Assistive Limb) lower-body exoskeleton, touted to be the world’s first cyborg – type robot, received a FDA...
PhaseBio poised to make rapid strides in the Anti-Coagulant Reversal Market
PhaseBio’s (NASDAQ: PHAS), PB2452 is the new drug on the block, which has received a breakthrough therapy status from the FDA in April...
